AI-generated summary
The authors report a non-randomised case series of 4 patients with type 2 diabetes and non-center-involving diabetic macular oedema, treated with far-red/near-infrared photobiomodulation for 2 to 9 months, with fellow eyes as untreated controls. They found a significant reduction in focal retinal thickening in all 4 treated eyes and no adverse effects attributable to therapy. The authors note that the study was small and that further studies are warranted.
- Participants
- 4
- Who or what was studied
- Four patients with type 2 diabetes and non-center-involving diabetic macular oedema (4 eyes), with fellow eyes as untreated controls.
- Limits stated in the abstract
- The study was a non-randomised case series with only 4 patients and no separate control group beyond fellow eyes, so the findings are preliminary.
Written by an AI model from this paper’s abstract only and checked automatically against it, but it can still be wrong. It is not medical advice. Read the full paper. See the editorial policy.
Abstract
The full abstract is not shown here because it is protected by the publisher’s copyright. Read it on bjo.bmj.com.
Record from PubMed, a service of the National Library of Medicine.
How to read a single study: what to check before relying on this kind of research.
Terms in this paper: Photobiomodulation, Near-infrared, Phototherapy. Each links to its definition in the glossary.
A summary of published research, not medical advice. One study rarely settles a question. See the disclaimer and how to read research.